CL2017002998A1 - Plantas que tienen expresión modificada de thca sintasa - Google Patents
Plantas que tienen expresión modificada de thca sintasaInfo
- Publication number
- CL2017002998A1 CL2017002998A1 CL2017002998A CL2017002998A CL2017002998A1 CL 2017002998 A1 CL2017002998 A1 CL 2017002998A1 CL 2017002998 A CL2017002998 A CL 2017002998A CL 2017002998 A CL2017002998 A CL 2017002998A CL 2017002998 A1 CL2017002998 A1 CL 2017002998A1
- Authority
- CL
- Chile
- Prior art keywords
- plants
- modified
- expression
- invention refers
- thca
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y121/00—Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21)
- C12Y121/03—Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21) with oxygen as acceptor (1.21.3)
- C12Y121/03007—Tetrahydrocannabinolic acid synthase (1.21.3.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
Abstract
<p>LA INVENCIÓN SE REFIERE A NUEVAS PLANTAS GENÉTICAMENTE MODIFICADAS Y MÉTODOS O MATERIALES, TALES COMO POLINUCLEÓTIDOS, CASETES DE EXPRESIÓN, O VECTORES, PARA SU PRODUCCIÓN. ADEMÁS, LA INVENCIÓN SE REFIERE A LA ALTERACIÓN DEL CONTENIDO DE CANNABINOIDES EN PLANTAS, Y A COMPOSICIONES MÉDICAS DERIVADAS DE DICHAS PLANTAS. EN PARTICULARES FORMAS DE REALIZACIÓN, LA PRESENTE INVENCIÓN SE REFIERE A PLANTAS DE CANNABIS QUE TIENEN EXPRESIÓN MODIFICADA DE ÁCIDO TETRAHIDROCANNABINÓLICO (THCA) SINTASA, Y MÉTODOS PARA MODIFICAR LA CANTIDAD DE DELTA-9—TETRAHIDOCANNABINOL (THC) Y CANNABIDIOL (CBD) EN CANNABIS, MODIFICANDO LA EXPRESIÓN DE THCA SINTASA.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562167462P | 2015-05-28 | 2015-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017002998A1 true CL2017002998A1 (es) | 2018-03-09 |
Family
ID=57393331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017002998A CL2017002998A1 (es) | 2015-05-28 | 2017-11-27 | Plantas que tienen expresión modificada de thca sintasa |
Country Status (14)
Country | Link |
---|---|
US (2) | US10934554B2 (es) |
EP (1) | EP3302033A4 (es) |
JP (1) | JP2018519853A (es) |
KR (1) | KR20180021718A (es) |
CN (1) | CN107846861A (es) |
AU (1) | AU2016269328A1 (es) |
BR (1) | BR112017025388A2 (es) |
CA (1) | CA2986666A1 (es) |
CL (1) | CL2017002998A1 (es) |
HK (1) | HK1252151A1 (es) |
IL (2) | IL255900B (es) |
MX (1) | MX2017015304A (es) |
RU (1) | RU2017146186A (es) |
WO (1) | WO2016189384A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017015304A (es) * | 2015-05-28 | 2018-07-06 | Tweed Inc | Plantas de cannabis que tienen expresion modificada de acido tetrahidrocannabinolico sintasa. |
EP3307756A4 (en) * | 2015-06-12 | 2019-01-02 | Anandia Laboratories Inc. | Methods and compositions for cannabis characterization |
US11466283B2 (en) * | 2016-08-18 | 2022-10-11 | Canopy Growth Corporation | Plants and methods for increasing and decreasing synthesis of cannabinoids |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
CN106591359B (zh) * | 2017-02-13 | 2019-10-25 | 黑龙江省科学院大庆分院 | 一种***THCA合成酶基因RNAi载体的构建方法 |
BR112019019966A2 (pt) | 2017-03-24 | 2020-04-28 | Trait Biosciences Inc | biossíntese in vivo de alto nível e isolamento de canabinoides solúveis em água em sistemas de plantas |
AU2018345673A1 (en) | 2017-10-03 | 2020-04-23 | Steep Hill, Inc. | Method for differentiating cannabis plant cultivars based on cannabinoid synthase paralogs |
GB2568032B (en) | 2017-10-25 | 2023-03-15 | Cell Science Holdings Ltd | A method of production of phytocannabinoids for use in medical treatments |
WO2019090017A1 (en) * | 2017-11-02 | 2019-05-09 | Yield10 Bioscience, Inc. | Genes and gene combinations for enhanced crops |
EP3724322A1 (en) | 2017-12-14 | 2020-10-21 | Medicinal Genomics Corporation | Methods and kits for classifying cannabinoid production in cannabis plants |
CA3089994A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
KR102374793B1 (ko) * | 2018-02-20 | 2022-03-17 | 엠와이엠디 파마슈티컬스 (플로리다), 인코포레이티드 | 물질 중독 및 다른 장애 치료용 유전자 변형 칸나비스 사티바 식물 및 변형된 칸나비노이드 화합물 |
WO2019199861A2 (en) | 2018-04-09 | 2019-10-17 | Ellevet Sciences | Hemp extract for treatment of pain in animals |
US11827892B2 (en) | 2018-06-07 | 2023-11-28 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Nucleic acid constructs and methods of using same |
US10897925B2 (en) * | 2018-07-27 | 2021-01-26 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
US20200035118A1 (en) | 2018-07-27 | 2020-01-30 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
WO2020035869A1 (en) * | 2018-08-17 | 2020-02-20 | Canbreed Ltd. | Modulation of cannabinoid profile in cannabis |
CN109122306A (zh) * | 2018-08-20 | 2019-01-04 | 杭州昶胜电子商务有限公司 | 一种获得高***二酚含量工业***植株的方法 |
WO2020077153A1 (en) | 2018-10-10 | 2020-04-16 | Canopy Holdings, LLC | Synthesis of cannabigerol |
BR112021009043A2 (pt) * | 2018-11-09 | 2021-10-26 | Agriculture Victoria Services Pty Ltd | Plantas de canábis com um perfil de canabinóide enriquecido para delta-9-tetrahidrocanabinol e canabigerol |
US10653085B1 (en) * | 2018-12-21 | 2020-05-19 | Charlotte's Web, Inc. | Hemp plant named ‘CW1AS1’ |
CA3130763A1 (en) | 2019-02-25 | 2020-09-03 | Ginkgo Bioworks, Inc. | Biosynthesis of cannabinoids and cannabinoid precursors |
WO2020183352A1 (en) * | 2019-03-12 | 2020-09-17 | Radient Technologies Innovations Inc. | Time specific bioavailability of extract in consumable |
US20220159922A1 (en) * | 2019-04-11 | 2022-05-26 | Kah Meng LIM | Process for producing a genetically modified seed |
US11999958B2 (en) * | 2019-07-17 | 2024-06-04 | Wisconsin Alumni Research Foundation | Methods of gene editing and transforming Cannabis |
CA3152016A1 (en) * | 2019-08-23 | 2021-03-04 | Canopy Growth Corporation | Methods for reducing thc content in complex cannabinoid mixtures in which thc is a minor component |
CN110419397A (zh) * | 2019-09-06 | 2019-11-08 | 黑龙江汉美生工业***科技有限公司 | 一种提高龙***5号cbd含量的种植管理方法 |
CA3153420A1 (en) * | 2019-09-06 | 2021-03-11 | James Berman | Genetic modification of plants |
CN114829381A (zh) * | 2019-10-01 | 2022-07-29 | 恩派瑞安神经科学公司 | 经遗传修饰的植物以及其制造方法 |
CA3152875A1 (en) * | 2019-10-01 | 2021-04-08 | Thomas Henley | Genetically modified plants and methods of making the same |
EP4041874A4 (en) * | 2019-10-11 | 2024-02-21 | National University of Singapore | BIOSYNTHESIS OF CANNABINOIDS FROM CANNABIGEROLIC ACID USING NOVEL CANNABINOID SYNTHASES |
US20230125534A1 (en) * | 2019-11-04 | 2023-04-27 | Agriculture Victoria Services Pty Ltd | A Method to Produce Targeted Gene Editing Constructs |
CN110923242B (zh) * | 2019-12-14 | 2021-04-13 | 厦门梓蔓生物科技有限公司 | 一种***腺毛中分离的转录因子CsAPL1及其应用 |
EP3841872A1 (en) | 2019-12-28 | 2021-06-30 | Ploidy and Genomics SL. | In vitro direct regeneration of polyploid cannabis plants |
WO2021138423A1 (en) * | 2019-12-30 | 2021-07-08 | Arcadia Biosciences, Inc. | Methods for genetically modifying cannabis plants, modified cannabis plants, and products therefrom |
CA3175033A1 (en) * | 2020-03-10 | 2021-05-20 | Phylos Bioscience, Inc. | Autoflowering markers |
CA3179868A1 (en) * | 2020-07-13 | 2022-01-20 | Betterseeds Ltd | Cannabis with altered cannabinoid content |
IL301056A (en) * | 2020-09-22 | 2023-05-01 | Growing Together Res Inc | Genetically modified cannabis plants with new phenotypes |
US12029720B2 (en) | 2021-04-29 | 2024-07-09 | Tilray Brands, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
WO2023015268A1 (en) * | 2021-08-06 | 2023-02-09 | Phylos Bioscience, Inc. | Varin genes |
EP4399304A1 (en) * | 2021-09-09 | 2024-07-17 | Agriculture Victoria Services Pty Ltd | Methods for the modification of cells, modified cells and uses thereof |
CN114214339A (zh) * | 2021-12-08 | 2022-03-22 | 福建农林大学 | 一种汉麻thcsas2基因及其编码产物萜烯酚酸氧化环化酶与应用 |
WO2023195781A1 (ko) * | 2022-04-05 | 2023-10-12 | 주식회사 진코어 | 유전자 교정 단백질을 포함하는 대마 유전자 교정용 조성물 및 이를 이용한 대마 유전자 교정 방법 |
USPP35571P2 (en) | 2023-05-05 | 2024-01-09 | Phat Panda LLC | Cannabis plant named ‘AC/DC x Redneck Wedding 13’ |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0596979T3 (da) | 1991-08-01 | 2002-05-13 | Large Scale Biology Corp | Rekombinante nucleinsyrer fra plantevirus |
WO1999053917A1 (en) | 1998-04-21 | 1999-10-28 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cannabinoids as antioxidants and neuroprotectants |
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
US7109245B2 (en) | 2001-08-15 | 2006-09-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vasoconstrictor cannabinoid analogs |
GB2439393B (en) | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
US9035130B2 (en) * | 2007-05-31 | 2015-05-19 | Gw Pharma Limited | Reference plant, a method for its production, extracts obtained therefrom and their use |
GB2450741A (en) | 2007-07-05 | 2009-01-07 | Gw Pharma Ltd | Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease |
GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
EP2341903A1 (en) | 2008-07-31 | 2011-07-13 | Bionorica Research GmbH | Cannabinoids for use in treating or preventing cognitive impairment and dementia |
US8884100B2 (en) * | 2009-08-12 | 2014-11-11 | National Research Council Of Canada | Aromatic prenyltransferase from Cannabis |
CA2796465C (en) | 2010-04-15 | 2021-10-19 | University Of Saskatchewan | Genes and proteins for aromatic polyketide synthesis |
US20120311744A1 (en) | 2011-06-06 | 2012-12-06 | Erich E. Sirkowski | Marked Cannabis For Indicating Medical Marijuana |
CA3130623A1 (en) * | 2011-07-13 | 2013-01-17 | National Research Council Of Canada | Genes and proteins for alkanoyl-coa synthesis |
US10441617B2 (en) * | 2013-03-15 | 2019-10-15 | Biotech Institute, Llc | Breeding, production, processing and use of medical cannabis |
WO2014145490A2 (en) * | 2013-03-15 | 2014-09-18 | Biotech Institute, Llc | Breeding, production, processing and use of specialty cannabis |
US20150098954A1 (en) | 2013-10-08 | 2015-04-09 | Elwha Llc | Compositions and Methods Related to CRISPR Targeting |
US9546960B2 (en) | 2014-11-14 | 2017-01-17 | Lightwave Science, Inc. | System and method for analysis of cannabis |
MX2017015304A (es) * | 2015-05-28 | 2018-07-06 | Tweed Inc | Plantas de cannabis que tienen expresion modificada de acido tetrahidrocannabinolico sintasa. |
-
2016
- 2016-05-27 MX MX2017015304A patent/MX2017015304A/es unknown
- 2016-05-27 US US15/577,708 patent/US10934554B2/en active Active
- 2016-05-27 CA CA2986666A patent/CA2986666A1/en active Pending
- 2016-05-27 CN CN201680030407.6A patent/CN107846861A/zh active Pending
- 2016-05-27 JP JP2018513926A patent/JP2018519853A/ja active Pending
- 2016-05-27 KR KR1020177036976A patent/KR20180021718A/ko unknown
- 2016-05-27 EP EP16799427.6A patent/EP3302033A4/en not_active Withdrawn
- 2016-05-27 BR BR112017025388-7A patent/BR112017025388A2/pt active Search and Examination
- 2016-05-27 AU AU2016269328A patent/AU2016269328A1/en not_active Abandoned
- 2016-05-27 WO PCT/IB2016/000814 patent/WO2016189384A1/en active Application Filing
- 2016-05-27 RU RU2017146186A patent/RU2017146186A/ru not_active Application Discontinuation
-
2017
- 2017-11-26 IL IL255900A patent/IL255900B/en active IP Right Grant
- 2017-11-27 CL CL2017002998A patent/CL2017002998A1/es unknown
-
2018
- 2018-09-07 HK HK18111542.0A patent/HK1252151A1/zh unknown
-
2020
- 2020-12-22 US US17/131,641 patent/US20210207154A1/en not_active Abandoned
-
2021
- 2021-03-15 IL IL281500A patent/IL281500B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2017146186A (ru) | 2019-06-28 |
CA2986666A1 (en) | 2016-12-01 |
JP2018519853A (ja) | 2018-07-26 |
IL255900A (en) | 2018-01-31 |
IL255900B (en) | 2021-04-29 |
AU2016269328A1 (en) | 2017-12-07 |
US20180258439A1 (en) | 2018-09-13 |
WO2016189384A1 (en) | 2016-12-01 |
IL281500B (en) | 2021-12-01 |
US10934554B2 (en) | 2021-03-02 |
EP3302033A4 (en) | 2018-10-31 |
US20210207154A1 (en) | 2021-07-08 |
RU2017146186A3 (es) | 2019-11-18 |
KR20180021718A (ko) | 2018-03-05 |
CN107846861A (zh) | 2018-03-27 |
HK1252151A1 (zh) | 2019-05-17 |
EP3302033A1 (en) | 2018-04-11 |
MX2017015304A (es) | 2018-07-06 |
IL281500A (en) | 2021-04-29 |
BR112017025388A2 (pt) | 2018-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002998A1 (es) | Plantas que tienen expresión modificada de thca sintasa | |
CL2020000632A1 (es) | Composición y método para el tratamiento del autismo. | |
CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
CO2017008437A2 (es) | Métodos de purificación de cannabinoides, composiciones y kits de los mismos | |
CO2017004974A2 (es) | Extractos de cannabis y métodos de preparación. | |
CL2017002650A1 (es) | Compuestos novedosos | |
EA201791299A1 (ru) | Микроинкапсулированные композиции каннабиноидов | |
MX2019000427A (es) | Formas de dosificacion oral de cannabinoide de alta concentracion. | |
BR112019001794A2 (pt) | composição de cannabis | |
CL2018002671A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj) | |
BR112017027567A2 (pt) | proteínas de fusão para inibir a angiogênese | |
UY36705A (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
AR102657A1 (es) | Composición para tratar telas | |
CL2018001621A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) | |
CO7081144A2 (es) | Anticuerpos biespecíficos contra tweak humana e il17 humana y usos de los mismos | |
BR112017013691A2 (pt) | composição compreendendo um polímero em multiestágio, seu método de preparação e seu uso | |
ECSP14013302A (es) | Composiciones de yodo-povidona estable | |
BR112017010177A2 (pt) | composição para tratamento de tecido | |
CU20180045A7 (es) | Productos de construcción que comprenden grafeno u óxido de grafeno en el material a granel y método para la producción de tales productos de construcción | |
BR112018003864A2 (pt) | método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido | |
CO2018001840A2 (es) | Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 | |
BR112017021191A2 (pt) | um extrato de indigo naturalis e um processo para preparar o mesmo | |
PE20200338A1 (es) | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil | |
CL2018003827A1 (es) | Nuevo extracto de aquenio silybum marianum y usos del mismo en la dermatología y dermocosméticos. | |
MX2017014092A (es) | Metodo para obtener una biomasa de una microalga de la especie tetraselmis chuii enriquecida en superoxido dismutasa (sod). |